ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

<< Previous

Bullboard Posts

Next >>

Post by DavidKingCanadaon Jul 21, 2021 12:40pm

197 Views

Post# 33581704

Business Advisory Board - Timothy G. Rothwell, JD

It seems we have some very well known people on the Business Advisory Board and the one that caught my Attention was Mr. Rothwell who is currently Chairman of Emisphere Technologies (OTC).

What does EMIS do?

Emisphere is a Commercial Stage Pharmaceutical and Drug "DELIVERY" Company.

When and if PMN commercializes their Serology Test or PMN310, do you think Mr. Rothwell and EMIS will carry us forward or is PMN have another Company in mind when it comes to distributing products to Big Pharma and Governments as they do not want to sell to Individuals.

Emis also bought Novo Nordisk which is massive Company based out of Denmark last year.

Thanks!

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing